Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We report the fourth case of
adenosine deaminase
(
ADA
) overproduction associated with hereditary nonspherocytic hemolytic anemia and the molecular analysis of this anomaly. The proband was a 10-year-old Japanese boy, who had an episode of
erythroblastosis fetalis
during the perinatal period. The red cell
ADA
activity showed a 110-fold increase and the red cell ATP level was about 64% of the comparably reticulocyte-rich controls, but the lymphocyte
ADA
activity was within the normal range. Western blotting of partially purified
ADA
from red cells revealed an increased amount of enzyme in the patient's red cells. No gene amplification or gene rearrangement was found by Southern blot analysis, and no increase of
ADA
mRNA in reticulocyte RNA was detected by dot blot analysis using
ADA
cDNA. We constructed a genomic DNA library and obtained three clones containing the 5'-promoter region of
ADA
gene. The 2.2 kb
ADA
promoter DNA fragment of these clones was fused to the chloramphenicol acetyl transferase (CAT) gene, and transfected to human erythroid cell line K562, and assayed for CAT activity. One of the clones, pADOP 2 cat, expressed about 2.6 times higher CAT activity than the normal
ADA
promoter fused to CAT gene in K562, but such enhancement was not seen in human non-erythroid cell lines; HL 60 and Raji. From these results, it is most likely, though not conclusive, that the 5' promotor fragment of the
ADA
gene of the patient was responsible for the cell-specific enhancement of protein synthesis.
...
PMID:Adenosine deaminase (ADA) overproduction associated with congenital hemolytic anemia: case report and molecular analysis. 316 80